| Literature DB >> 29158711 |
Liljana Bogdanovska1, Ana Poceva Panovska1, Mirjana Popovska2, Aneta Dimitrovska1, Rumenka Petkovska1.
Abstract
The process of assessment of drug efficacy produces multivariate data which are difficult to interpret. The interpretation and extraction of relevant data requires application of chemometric algorithms for multivariate data analysis. The aim of our study was evaluation of the efficacy of local treatment with chlorhexidine (CHX) in patients suffering from periodontal disease by chemometric algorithms for multivariate data analysis. Several algorithms were used: principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal projection to latent structures discriminant analysis (OPLS-DA). The PCA models identified the examined variables as suitable for monitoring the periodontal disease progression at the same time revealing mutual relationship among them. The developed PLS-DA model successfully distinguished patients treated with CHX from non-treated patients. The OPLS-DA model revealed differences in the mechanism of action of the two widely applied treatments in periodontal disease, local administration of CHX and local administration of doxycycline (DOX). The approach presented in this study opens the possibility of application of chemometric algorithms for multivariate data analysis for assessment of treatment efficacy.Entities:
Keywords: ALP, alkaline phosphatase; AST, aspartate aminotransferase; CAL, clinical attachment loss; CHX, chlorhexidine; Chemometric algorithms; Chlorhexidine; DOX, doxycycline; GCF, gingival crevicular fluid; GI, index of gingival inflammation; IL-1β, interleukin -1 beta; LDH, lactate dehydrogenase; Multivariate data analysis; OPLS-DA, orthogonal projection to latent structures discriminant analysis; PCA, principal component analysis; PD, pocket depth; PLS-DA, partial least square discriminant analysis; Periodontal disease; TNF, α- tumor necrosis factor-alpha; Treatment efficacy; VIP, variable influence on projection
Year: 2017 PMID: 29158711 PMCID: PMC5681301 DOI: 10.1016/j.jsps.2017.03.006
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Results from determination of inflammatory biomarkers in GCF samples and clinical indices in the control group.
| N° | ALP (IU/L) | LDH (IU/L) | AST (IU/L) | IL-1β (pg mL−1) | TNF-α (pg mL−1) | GI | CAL (mm) | PD (mm) |
|---|---|---|---|---|---|---|---|---|
| 1 | 37.3 | 263.1 | 26.7 | 27.3 | 35.6 | 2 | 2 | 2 |
| 2 | 24.9 | 251.0 | 6.7 | 31.2 | 15.6 | 1 | 1 | 1 |
| 3 | 7.3 | 89.5 | 10.0 | 15.6 | 12.4 | 1 | 2 | 1 |
| 4 | 14.9 | 36.4 | 26.7 | 17.4 | 18.0 | 1 | 1 | 1 |
| 5 | 29.7 | 99.5 | 13.3 | 31.2 | 18.7 | 1 | 2 | 1 |
| 6 | 27.3 | 111.0 | 13.3 | 15.6 | 20.4 | 1 | 1 | 1 |
| 7 | 29.6 | 384.9 | 16.7 | 17.4 | 21.8 | 1 | 1 | 1 |
| 8 | 17.6 | 99.9 | 20.0 | 35.9 | 18.5 | 1 | 1 | 1 |
| 9 | 19.0 | 389.6 | 16.7 | 29.0 | 15.6 | 1 | 1 | 1 |
N°- number of GCF samples from the control group.
GI – expressed as values ranging from 1 дo 3.
Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients before and after local administration of CHX.
| Results obtained before the local CHX treatment | Results obtained after the local CHX treatment | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | N | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 1 | 49.8 | 267.1 | 15.0 | 191.4 | 26.3 | 3 | 5 | 3 | 35 | 22.1 | 437.1 | 48.3 | 214.1 | 25.9 | 1 | 2 | 3 |
| 2 | 58.0 | 518.1 | 33.3 | 448.2 | 33.2 | 2 | 4 | 4 | 36 | 16.3 | 342.2 | 30.7 | 8.5 | 20.1 | 1 | 2 | 3 |
| 3 | 53.9 | 769.0 | 98.3 | 445.9 | 25.2 | 2 | 4 | 5 | 37 | 29.0 | 28.3 | 200.0 | 8.5 | 25.9 | 1 | 2 | 3 |
| 4 | 26.3 | 445.2 | 36.7 | 465.3 | 22.6 | 2 | 3 | 3 | 38 | 41.5 | 81.0 | 28.3 | 623.8 | 33.4 | 1 | 2 | 3 |
| 5 | 38.7 | 534.3 | 36.7 | 332.9 | 30.1 | 1 | 6 | 5 | 39 | 31.8 | 388.6 | 80.0 | 129.7 | 49.9 | 1 | 3 | 2 |
| 6 | 42.8 | 854.0 | 81.7 | 416.3 | 36.3 | 1 | 5 | 4 | 40 | 55.3 | 1447.4 | 55.0 | 172.4 | 45.6 | 1 | 2 | 3 |
| 7 | 56.7 | 740.7 | 25.0 | 356.3 | 24.2 | 2 | 4 | 3 | 41 | 69.0 | 1094.0 | 55.0 | 408.3 | 45.9 | 2 | 3 | 3 |
| 8 | 59.4 | 1376.2 | 61.7 | 167.5 | 42.9 | 2 | 5 | 4 | 42 | 27.6 | 696.2 | 106.7 | 73.6 | 21.6 | 2 | 2 | 3 |
| 9 | 53.9 | 902.6 | 115 | 153.3 | 29.9 | 2 | 5 | 4 | 43 | 36.8 | 562.4 | 33.3 | 114.4 | 21.6 | 1 | 4 | 2 |
| 10 | 47.0 | 967.4 | 53.3 | 103.2 | 18.9 | 3 | 5 | 3 | 44 | 34.2 | 1461.1 | 41.7 | 166.5 | 28.6 | 2 | 4 | 2 |
| 11 | 48.4 | 765.0 | 50.0 | 143.2 | 38.2 | 2 | 4 | 2 | 45 | 32.8 | 611.2 | 26.7 | 131.2 | 30.6 | 1 | 2 | 2 |
| 12 | 53.9 | 1024.1 | 33.3 | 125.4 | 32.9 | 2 | 3 | 4 | 46 | 48.4 | 789.3 | 56.7 | 300.3 | 20.4 | 2 | 4 | 4 |
| 13 | 47.0 | 655.7 | 13.3 | 79.6 | 40.9 | 2 | 4 | 5 | 47 | 29.3 | 627.5 | 44.2 | 173.7 | 35.6 | 2 | 2 | 2 |
| 14 | 72.6 | 1255.9 | 64.9 | 261.4 | 43.1 | 2 | 4 | 4 | 48 | 25.4 | 459.3 | 54.4 | 200.4 | 28.9 | 2 | 3 | 4 |
| 15 | 80.0 | 455.9 | 98.4 | 146.1 | 46.3 | 2 | 4 | 5 | 49 | 20.1 | 168.3 | 24.2 | 145.7 | 25.9 | 1 | 2 | 3 |
| 16 | 39.5 | 955.4 | 71.9 | 407.2 | 50.9 | 2 | 3 | 3 | 50 | 16.3 | 336.7 | 29.0 | 220.0 | 20.1 | 1 | 2 | 3 |
| 17 | 45.6 | 1000.7 | 65.4 | 294.5 | 63.1 | 3 | 6 | 5 | 51 | 20.0 | 459.3 | 31.7 | 204.5 | 25.9 | 1 | 2 | 3 |
| 18 | 45.6 | 1432.9 | 55.3 | 228.4 | 31.0 | 3 | 5 | 4 | 52 | 31.5 | 498.7 | 28.6 | 178.3 | 33.4 | 1 | 2 | 3 |
| 19 | 75.0 | 851.4 | 39.0 | 322.3 | 30.0 | 2 | 4 | 3 | 53 | 31.5 | 627.5 | 24.6 | 322.3 | 49.9 | 1 | 3 | 2 |
| 20 | 78.6 | 669.3 | 43.0 | 461.7 | 25.4 | 2 | 3 | 2 | 54 | 38.4 | 269.2 | 39.2 | 359.6 | 33.4 | 1 | 1 | 1 |
| 21 | 62.4 | 422.0 | 47.0 | 271.4 | 37.3 | 2 | 5 | 4 | 55 | 56.2 | 437.1 | 52.4 | 171.2 | 45.6 | 1 | 2 | 3 |
| 22 | 65.6 | 536.9 | 35.9 | 309.8 | 41.0 | 2 | 4 | 3 | 56 | 26.6 | 342.2 | 53.7 | 309.7 | 45.9 | 2 | 3 | 3 |
| 23 | 71.4 | 991.0 | 40.7 | 204.0 | 44.1 | 2 | 5 | 4 | 57 | 22.4 | 28.3 | 23.7 | 178.6 | 21.6 | 2 | 2 | 3 |
| 24 | 76.3 | 887.9 | 75.4 | 125.0 | 40.3 | 3 | 5 | 4 | 58 | 34.2 | 81.0 | 35.7 | 125.0 | 21.6 | 1 | 4 | 2 |
| 25 | 43.6 | 731.8 | 70.2 | 181.9 | 26.0 | 2 | 4 | 2 | 59 | 42.8 | 388.6 | 20.6 | 157.9 | 28.6 | 2 | 4 | 2 |
| 26 | 53.9 | 602.0 | 45.0 | 168.7 | 29.7 | 2 | 3 | 4 | 60 | 38.4 | 157.9 | 48.3 | 129.0 | 30.6 | 1 | 2 | 2 |
| 27 | 78.9 | 731.7 | 37.9 | 300.3 | 24.1 | 2 | 4 | 5 | 61 | 42.8 | 1447.4 | 30.7 | 225.3 | 20.4 | 2 | 4 | 4 |
| 28 | 61.0 | 376.7 | 46.7 | 287.7 | 33.7 | 3 | 6 | 5 | 62 | 29.3 | 1094.0 | 26.7 | 257.3 | 26.9 | 1 | 3 | 2 |
| 29 | 65.4 | 920.5 | 57.5 | 259.7 | 27.5 | 3 | 4 | 3 | 63 | 25.4 | 696.2 | 28.3 | 173.7 | 29.0 | 1 | 2 | 1 |
| 30 | 55.5 | 554.9 | 45.4 | 146.1 | 33.1 | 3 | 2 | 4 | 64 | 29.0 | 874.9 | 80.0 | 103.7 | 25.1 | 2 | 2 | 2 |
| 31 | 37.3 | 263.1 | 26.7 | 274.4 | 35.6 | 2 | 2 | 2 | 65 | 22.1 | 437.1 | 48.3 | 214.1 | 25.9 | 1 | 2 | 3 |
| 32 | 24.9 | 250.9 | 6.7 | 31.2 | 15.6 | 1 | 1 | 1 | 66 | 16.3 | 342.2 | 30.7 | 8.5 | 20.1 | 1 | 2 | 3 |
| 33 | 27.3 | 263.1 | 26.7 | 274.4 | 35.6 | 2 | 2 | 2 | 67 | 29.0 | 28.3 | 200.0 | 8.5 | 25.9 | 1 | 2 | 3 |
| 34 | 31.8 | 473.6 | 31.7 | 507.3 | 28.9 | 2 | 3 | 4 | 68 | 41.5 | 81.0 | 28.3 | 623.8 | 33.4 | 1 | 2 | 3 |
1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL−1); 5 - TNF-α concentration (pg mL−1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm).
Fig. 1Score plots of PCA model of data set from the control group of volunteers and periodontal patients before local administration of CHX (Hotteling’s ellipse). (A) Identification of outliers by the PCA model (B) PCA model after exclusion of outliers, the left cluster of points belongs to the control group (C), the right cluster to periodontitis patients before local administration of CHX.
Fig. 2Loading plot for PC1 and PC2 showing variables that enable discrimination between control group of and periodontal patients before administration of CHX.
Fig. 3PCA model of patient’s data taken before and after the local administration of CHX. The score plot shows the model’s inability for data discrimination.
Correlation coefficients among selected variables in patients before and after local administration of CHX. Significant correlations are bolded.
| ALP | LDH | AST | IL-1β | TNF-α | GI | CAL | PD | |
|---|---|---|---|---|---|---|---|---|
| 1.000 | 0.378 | 0.269 | 0.169 | 0.304 | ||||
| LDH | 1.000 | 0.348 | −0.028 | 0.170 | 0.281 | 0.341 | 0.267 | |
| AST | 1.000 | −0.015 | 0.222 | 0.192 | 0.196 | 0.233 | ||
| IL-1β | 1.000 | 0.085 | 0.052 | 0.138 | 0.148 | |||
| TNF-α | 1.000 | 0.122 | 0.175 | 0.137 | ||||
| GI | 1.000 | 0.502 | 0.438 | |||||
| CAL | 1.000 | 0.592 | ||||||
| PD | 1.000 |
CHX concentrations in patient’s GCF samples after the local treatment.
| Patient N° | CHX (µg mL−1) | Patient N° | CHX (µg mL−1) |
|---|---|---|---|
| 1 | 154.12 | 18 | 135.39 |
| 2 | 122.05 | 19 | 187.84 |
| 3 | 133.07 | 20 | 156.96 |
| 4 | 135.39 | 21 | 126.05 |
| 5 | 167.84 | 22 | 122.92 |
| 6 | 156.96 | 23 | 164.39 |
| 7 | 136.05 | 24 | 145.36 |
| 8 | 164.39 | 25 | 139.82 |
| 9 | 139.82 | 26 | 149.82 |
| 10 | 139.82 | 27 | 126.79 |
| 11 | 126.79 | 28 | 135.21 |
| 12 | 130.21 | 29 | 137.82 |
| 13 | 147.82 | 30 | 159.25 |
| 14 | 169.25 | 31 | 100.36 |
| 15 | 174.12 | 32 | 112.69 |
| 16 | 125.05 | 33 | 135.39 |
| 17 | 123.07 | 34 | 187.24 |
Fig. 4Representative chromatogram of a patient’s GCF sample after the local administration of CHX (1-chlorpheniramine (internal standard), 2-CHX).
Fig. 5PLS-DA score plot of data (GCF inflammatory biomarkers, clinical indices and CHX concentration in GCF) before and after the local administration of CHX. Squares clustered to left represent data before treatment, whereas squares clustered to the right represent data after treatment with CHX.
Fig. 6Validation of the PLS-DA model using permutation testing. Each symbol represents a permutation result, R2 is represented by green squares and Q2 by blue squares.
Fig. 7VIP statistics plot of the X-variables of the three component PLS-DA model for efficacy evaluation of local administration of CHX.
Results from determination of inflammatory biomarkers in GCF samples and clinical indices in periodontal patients after the local treatment with DOX.
| N° | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| 1 | 41.5 | 226.7 | 8.3 | 15.6 | 21.9 | 1 | 2 | 2 |
| 2 | 16.6 | 137.6 | 20.0 | 33.6 | 23.3 | 1 | 1 | 1 |
| 3 | 6.9 | 668.8 | 16.7 | 24.0 | 22.9 | 1 | 1 | 1 |
| 4 | 22.1 | 741.6 | 16.7 | 89.0 | 29.0 | 1 | 1 | 1 |
| 5 | 18.0 | 429.0 | 16.7 | 55.4 | 15.6 | 1 | 2 | 2 |
| 6 | 38.7 | 416.9 | 16.7 | 62.5 | 23.7 | 1 | 1 | 1 |
| 7 | 24.9 | 53.3 | 2.3 | 31.8 | 7.8 | 1 | 1 | 1 |
| 8 | 27.6 | 315.7 | 7.8 | 42.2 | 17.7 | 1 | 2 | 2 |
| 9 | 42.8 | 267.1 | 15.0 | 162.0 | 22.9 | 1 | 1 | 1 |
| 10 | 52.5 | 1003.1 | 73.3 | 37.6 | 19.6 | 1 | 2 | 3 |
| 11 | 38.7 | 505.9 | 56.7 | 95.5 | 30.6 | 1 | 3 | 2 |
| 12 | 19.3 | 1044.3 | 25.0 | 146.8 | 35.2 | 1 | 3 | 2 |
| 13 | 34.6 | 1291.2 | 35.0 | 136.4 | 15.6 | 2 | 3 | 1 |
| 14 | 31.8 | 1894.9 | 103.3 | 56.9 | 35.6 | 1 | 2 | 2 |
| 15 | 52.5 | 918.8 | 70.0 | 47.8 | 23.2 | 1 | 2 | 3 |
| 16 | 33.2 | 323.8 | 16.7 | 221.8 | 33.9 | 1 | 4 | 2 |
| 17 | 66.3 | 1076.2 | 30.0 | 301.4 | 42.9 | 1 | 3 | 1 |
| 18 | 24.9 | 344.0 | 56.7 | 156.4 | 15.6 | 1 | 2 | 1 |
| 19 | 16.0 | 429.0 | 16.7 | 125.4 | 15.6 | 1 | 2 | 2 |
| 20 | 35.7 | 416.9 | 16.7 | 62.5 | 23.7 | 1 | 2 | 3 |
| 21 | 20.9 | 789.3 | 28.3 | 31.8 | 7.8 | 1 | 4 | 2 |
| 22 | 21.7 | 315.7 | 7.8 | 221.8 | 17.7 | 1 | 3 | 1 |
| 23 | 38.7 | 267.1 | 15.0 | 162.0 | 22.9 | 1 | 2 | 1 |
| 24 | 52.5 | 283.1 | 73.3 | 137.6 | 19.6 | 1 | 3 | 2 |
| 25 | 38.7 | 505.9 | 56.7 | 95.5 | 30.6 | 2 | 2 | 2 |
1- ALP activity (IU/L); 2-LDH activity (IU/L); 3- AST activity (IU/L); 4 - IL-1β concentration (pg mL-1); 5 - TNF-α concentration (pg mL-1); 6- GI index (1–3); 7-CAL (mm); 8-PD (mm).
Fig. 8Score plot of the OPLS-DA model of data obtained after the local administration of CHX and after local administration of DOX in periodontal patients.
Fig. 9VIP statistics plot of the X-variables of the OPLS-DA model for comparative evaluation of efficacy of local administration of CHX and local administration of DOX.